Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Metsera
Developing next-gen obesity therapies
Biotech
Metsera posts amylin data, eyes monthly GLP-1 combo
Metsera saw 8.4% placebo-adjusted weight loss at Day 36, advancing its push to challenge AbbVie, Eli Lilly, Novo Nordisk and Roche.
Nick Paul Taylor
Jun 9, 2025 7:00am
Biotech's top money raisers: 2024
Mar 3, 2025 5:00am
Metsera, Maze go public with IPOs of $275M, $113M
Jan 31, 2025 7:40am
Metsera eyes $289M IPO to fund phase 3 weight loss trial
Jan 27, 2025 11:00am
Obesity biotech Metsera files for a swift IPO
Jan 11, 2025 9:05am
Metsera links GLP-1 drug to 11% weight loss after 12 weeks
Jan 7, 2025 8:32am
